Phentermine plus topiramate for the treatment of obesity

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 5, 2012, Pages 503-510

  Powell, Amanda ^a   Aronne, Louis J ^b   Apovian, Caroline M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

combination therapy; obesity; phentermine; topiramate; weight loss

Indexed keywords

BICARBONATE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TOPIRAMATE;

ANXIETY DISORDER; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; BICARBONATE BLOOD LEVEL; CHEMOPROPHYLAXIS; COGNITION; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; CONTROLLED DRUG RELEASE; DEPRESSION; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG LEGISLATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; HEADACHE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MOOD; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84867628805     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.43     Document Type: Review

References (26)

1. Barness LA, Opitz JM, Gilbert-Bar ness E. Obesity: genetic, molecular, and environmental aspects. Am. J. Med. Genet. A 143A(24), 3016-3034 (2007). (Pubitemid 350274816)
2. Whitlock G, Lewington S, Sherliker P et al.; Prospective Studies Collaboration. Body-mass index and cause-specifc mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373(9669), 1083-1096 (2009).
3. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307(5), 491-497 (2012).
4. Knowler WC, Barrett-Connor E, Fowler SE et al.;The Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002). (Pubitemid 34437694)
5. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155(7), 434-447 (2011).
6. Melnikova I, Wages D. Anti-obesity therapies. Nat. Rev. Drug Discov. 5(5), 369-370 (2006). (Pubitemid 43904927)
7. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes. Rev. 1(2), 121-126 (2000).
8. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity Clin. Pharmacol. Ther. 90(1), 40-51 (2011).
9. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 18(9), 1739-1746 (2010).
10. Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci. Ther. 14(2), 120-142 (2008). (Pubitemid 351713317)
11. Topamax, package insert. Janssen Pharmaceuticals, NJ, USA.
12. Appolinario JC, Bueno JR, Coutinho W Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs 18(10), 629-651 (2004). (Pubitemid 39141771)
13. Bray GA, Hollander P, Klein S, et al A 6 month randomized, placebo-controlled dose-ranging trial of Topiramate for weight loss in obesity. Obes. Res. 11, 722-733 (2003). (Pubitemid 41151598)
14. Coman E. Anorectics on trial; a half century of regulation of prescription appetite suppressants. Ann. Intern. Med. 143(5), 380-385 (2005).
15. VI-0521 (QNEXA®) Advisory Committee Briefng Document, NDA 022580, Vivus, Inc., 15 July 2010.
16. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin. Emerg Drugs 13(2), 383-392 (2008). (Pubitemid 351957352)
17. Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes. Res. 12(Suppl.), S167-S173 (2004).
18. VI-0521 (Qnexa®) Advisory Committee Briefng Document NDA 022580, Vivus Pharmaceuticals, 22 February 2012.
19. Allison DB, Gadde KM, Garvey WT, et al Controlled release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 20(2), 330-342 (2012).
20. Gadde KM, Allison DB, Ryan DH et al Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341-1352 (2011).
21. Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefts with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase 3 extension study. Am. J. Clin. Nutr. 95(2), 297-308 (2012).
22. White WB. Heart rate and rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am. J. Hypertens. 12(2), S50-S55 (1999).
23. Vajda FJE, Graham J, Roten A, Lander CM, O'Brien TJ, Eadie, M. Teratogenicity of newer antiepileptic drugs, the Australian experience. J. Clin. Neurophysiol. 19(1), 57-59 (2012).
24. Sjöström L, Narbro K, Sjöström CD et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357(8), 741-752 (2007). (Pubitemid 47295641)
25. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfuramine and phentermine alone and in combination. Arch. Intern. Med. 144(6), 1143-1148 (1984). (Pubitemid 14121061)
26. Glazer, G. Long-term pharmacotherapy of Obesity 2000. Arch. Intern. Med. 161 (15), 1814-1824 (2001).